In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

William G. Herrington,Doreen Zhu,Richard Haynes

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

2019

William G. Herrington
Doreen Zhu
Richard Haynes

Source Citation Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537-50. 29941478

Keywords:

Renal function
Canagliflozin
Cardiology
Internal medicine
Diabetes mellitus
Medicine
cardiovascular event

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations